Idsk -- BOSTON (EGMN) –The risk of Legionnaires’ disease associated with tumor necrosis factor-alpha antagonist therapy is greatest during the first year of treatment and is significantly higher for patients receiving adalimumab or infliximab, compared with etanercept, according to a study reported Sept. 15 at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
